(Q38140118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Ana Espirito Santo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

22 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1625-1634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture.

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Cancer stem cells: back to Darwin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Drug-resistant mutants of Chinese hamster ovary cells possess an altered cell surface carbohydrate component

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

A "silent" polymorphism in the MDR1 gene changes substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Multidrug resistance (MDR-1) expression in AIDS-related lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Multidrug resistance in AIDS-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

MDR1 Gene C1236T and C6+139T polymorphisms in the Russian population: associations with predisposition to lymphoproliferative diseases and drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Synthesis of some novel benzofuran-2-yl(4,5-dihyro-3,5-substituted diphenylpyrazol-1-yl) methanones and studies on the antiproliferative effects and reversal of multidrug resistance of human MDR1-gene transfected mouse lymphoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Differential Effect of HIV-1 Protease Inhibitors on P-Glycoprotein Function in Multidrug-Resistant Variants of the Human CD4+ T Lymphoblastoid CEM Cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

21 January 2018

Cyclosporine: a review

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Cyclosporin A is a broad-spectrum multidrug resistance modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.835803

10.1517/17425255.2013.835803

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24053936%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference